organization · Reporting owner
Q-Ventures Program II (Co-Invest Holdings) Ltd.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Vir Biotechnology, Inc.
Report date October 16, 2019 · Filed October 18, 2019
Jointly reported with Angella Frank G., Quinn Christopher
Section 16 reporting ended · disclosed 2019-10-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,666,666 |
Last balance in matching sequence
After 2019-10-16 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2019-10-16 · Conversion · Acquired 1,111,111 · Balance 1,111,111 F2: The Series A-1 Convertible Preferred Stock ("Series A") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the Issuer's public offering of Common Stock pursuant to the Issuer's registration statement under the Securities Act of 1933, as amended, filed with the Securities and Exchange Commission on September 3, 2019, as amended on September 30, 2019 (the "IPO"). The Series A had no expiration date. F1: The reported securities are beneficially owned by Q-Ventures Program II (Co-Invest Holdings) Ltd. ("Q-Ventures"). Frank Angella and Christopher Quinn are the directors of Q-Ventures and have shared voting and investment power over the shares held by Q-Ventures and, as a result, may each be deemed to beneficially own the reported securities. Each of the Reporting Persons disclaims beneficial ownership of the reported securities, except to the extent of his or its pecuniary interest therein. Row 2 · 2019-10-16 · Conversion · Acquired 555,555 · Balance 1,666,666 F3: The Series B Convertible Preferred Stock ("Series B") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the IPO. The Series B had no expiration date. F1: The reported securities are beneficially owned by Q-Ventures Program II (Co-Invest Holdings) Ltd. ("Q-Ventures"). Frank Angella and Christopher Quinn are the directors of Q-Ventures and have shared voting and investment power over the shares held by Q-Ventures and, as a result, may each be deemed to beneficially own the reported securities. Each of the Reporting Persons disclaims beneficial ownership of the reported securities, except to the extent of his or its pecuniary interest therein. |
| Series A-1 Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-10-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-10-16 · Conversion · Disposed 1,111,111 · Balance 0 F2: The Series A-1 Convertible Preferred Stock ("Series A") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the Issuer's public offering of Common Stock pursuant to the Issuer's registration statement under the Securities Act of 1933, as amended, filed with the Securities and Exchange Commission on September 3, 2019, as amended on September 30, 2019 (the "IPO"). The Series A had no expiration date. F1: The reported securities are beneficially owned by Q-Ventures Program II (Co-Invest Holdings) Ltd. ("Q-Ventures"). Frank Angella and Christopher Quinn are the directors of Q-Ventures and have shared voting and investment power over the shares held by Q-Ventures and, as a result, may each be deemed to beneficially own the reported securities. Each of the Reporting Persons disclaims beneficial ownership of the reported securities, except to the extent of his or its pecuniary interest therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-10-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-10-16 · Conversion · Disposed 555,555 · Balance 0 F3: The Series B Convertible Preferred Stock ("Series B") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the IPO. The Series B had no expiration date. F1: The reported securities are beneficially owned by Q-Ventures Program II (Co-Invest Holdings) Ltd. ("Q-Ventures"). Frank Angella and Christopher Quinn are the directors of Q-Ventures and have shared voting and investment power over the shares held by Q-Ventures and, as a result, may each be deemed to beneficially own the reported securities. Each of the Reporting Persons disclaims beneficial ownership of the reported securities, except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are beneficially owned by Q-Ventures Program II (Co-Invest Holdings) Ltd. ("Q-Ventures"). Frank Angella and Christopher Quinn are the directors of Q-Ventures and have shared voting and investment power over the shares held by Q-Ventures and, as a result, may each be deemed to beneficially own the reported securities. Each of the Reporting Persons disclaims beneficial ownership of the reported securities, except to the extent of his or its pecuniary interest therein.
F2: The Series A-1 Convertible Preferred Stock ("Series A") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the Issuer's public offering of Common Stock pursuant to the Issuer's registration statement under the Securities Act of 1933, as amended, filed with the Securities and Exchange Commission on September 3, 2019, as amended on September 30, 2019 (the "IPO"). The Series A had no expiration date.
F3: The Series B Convertible Preferred Stock ("Series B") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the IPO. The Series B had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 16, 2019 Filed Oct 18, 2019 20:21 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionSeries B Convertible Preferred Stock · Derivative | 555,555 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-025772 · doc4.xml · derivative · entry 4 Q-Ventures Program II (Co-Invest Holdings) Ltd. · CIK 0001790363 · Former 10% Holder Angella Frank G. · CIK 0001791076 · Former 10% Holder Quinn Christopher · CIK 0001791072 · Former 10% Holder Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 555,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series B Convertible Preferred Stock ("Series B") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the IPO. The Series B had no expiration date. F3 · derivative.exercise_date: The Series B Convertible Preferred Stock ("Series B") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the IPO. The Series B had no expiration date. F3 · derivative.expiration_date: The Series B Convertible Preferred Stock ("Series B") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the IPO. The Series B had no expiration date. F1 · ownership.direct: The reported securities are beneficially owned by Q-Ventures Program II (Co-Invest Holdings) Ltd. ("Q-Ventures"). Frank Angella and Christopher Quinn are the directors of Q-Ventures and have shared voting and investment power over the shares held by Q-Ventures and, as a result, may each be deemed to beneficially own the reported securities. Each of the Reporting Persons disclaims beneficial ownership of the reported securities, except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 20:21 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 1,111,111 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-025772 · doc4.xml · derivative · entry 3 Q-Ventures Program II (Co-Invest Holdings) Ltd. · CIK 0001790363 · Former 10% Holder Angella Frank G. · CIK 0001791076 · Former 10% Holder Quinn Christopher · CIK 0001791072 · Former 10% Holder Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,111,111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A-1 Convertible Preferred Stock ("Series A") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the Issuer's public offering of Common Stock pursuant to the Issuer's registration statement under the Securities Act of 1933, as amended, filed with the Securities and Exchange Commission on September 3, 2019, as amended on September 30, 2019 (the "IPO"). The Series A had no expiration date. F2 · derivative.exercise_date: The Series A-1 Convertible Preferred Stock ("Series A") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the Issuer's public offering of Common Stock pursuant to the Issuer's registration statement under the Securities Act of 1933, as amended, filed with the Securities and Exchange Commission on September 3, 2019, as amended on September 30, 2019 (the "IPO"). The Series A had no expiration date. F2 · derivative.expiration_date: The Series A-1 Convertible Preferred Stock ("Series A") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the Issuer's public offering of Common Stock pursuant to the Issuer's registration statement under the Securities Act of 1933, as amended, filed with the Securities and Exchange Commission on September 3, 2019, as amended on September 30, 2019 (the "IPO"). The Series A had no expiration date. F1 · ownership.direct: The reported securities are beneficially owned by Q-Ventures Program II (Co-Invest Holdings) Ltd. ("Q-Ventures"). Frank Angella and Christopher Quinn are the directors of Q-Ventures and have shared voting and investment power over the shares held by Q-Ventures and, as a result, may each be deemed to beneficially own the reported securities. Each of the Reporting Persons disclaims beneficial ownership of the reported securities, except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 20:21 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionCommon Stock | 555,555 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-025772 · doc4.xml · nonDerivative · entry 2 Q-Ventures Program II (Co-Invest Holdings) Ltd. · CIK 0001790363 · Former 10% Holder Angella Frank G. · CIK 0001791076 · Former 10% Holder Quinn Christopher · CIK 0001791072 · Former 10% Holder Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,666,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series B Convertible Preferred Stock ("Series B") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the IPO. The Series B had no expiration date. F1 · ownership.direct: The reported securities are beneficially owned by Q-Ventures Program II (Co-Invest Holdings) Ltd. ("Q-Ventures"). Frank Angella and Christopher Quinn are the directors of Q-Ventures and have shared voting and investment power over the shares held by Q-Ventures and, as a result, may each be deemed to beneficially own the reported securities. Each of the Reporting Persons disclaims beneficial ownership of the reported securities, except to the extent of his or its pecuniary interest therein. Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 20:21 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | ConversionCommon Stock | 1,111,111 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-025772 · doc4.xml · nonDerivative · entry 1 Q-Ventures Program II (Co-Invest Holdings) Ltd. · CIK 0001790363 · Former 10% Holder Angella Frank G. · CIK 0001791076 · Former 10% Holder Quinn Christopher · CIK 0001791072 · Former 10% Holder Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,111,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series A-1 Convertible Preferred Stock ("Series A") converted automatically into shares of the Issuer's Common Stock on a 1-for-1 basis upon the completion of the Issuer's public offering of Common Stock pursuant to the Issuer's registration statement under the Securities Act of 1933, as amended, filed with the Securities and Exchange Commission on September 3, 2019, as amended on September 30, 2019 (the "IPO"). The Series A had no expiration date. F1 · ownership.direct: The reported securities are beneficially owned by Q-Ventures Program II (Co-Invest Holdings) Ltd. ("Q-Ventures"). Frank Angella and Christopher Quinn are the directors of Q-Ventures and have shared voting and investment power over the shares held by Q-Ventures and, as a result, may each be deemed to beneficially own the reported securities. Each of the Reporting Persons disclaims beneficial ownership of the reported securities, except to the extent of his or its pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.